Cargando…

How are new drugs disseminated in Japan? Analysis using the National Database of Health Insurance Claims of Japan

Drug lag refers to the difference in the time of a new drug's approval in different countries; the dissemination of the new drug after approval within the countries is another problem. We examined the nationwide dissemination of 11 cancer drugs approved in Japan between 2011 and 2015 using the...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Tomone, Sugiyama, Takehiro, Imai, Kenjiro, Higashi, Takahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128186/
https://www.ncbi.nlm.nih.gov/pubmed/35266252
http://dx.doi.org/10.1111/cas.15322
_version_ 1784712511170281472
author Watanabe, Tomone
Sugiyama, Takehiro
Imai, Kenjiro
Higashi, Takahiro
author_facet Watanabe, Tomone
Sugiyama, Takehiro
Imai, Kenjiro
Higashi, Takahiro
author_sort Watanabe, Tomone
collection PubMed
description Drug lag refers to the difference in the time of a new drug's approval in different countries; the dissemination of the new drug after approval within the countries is another problem. We examined the nationwide dissemination of 11 cancer drugs approved in Japan between 2011 and 2015 using the National Database of Health Insurance Claims data. We extracted data on the number of cancer drug prescriptions from 47 prefectures and associated demographic information, such as age and sex. Eight diabetes drugs were also examined for comparison. We observed a lag between the marketing approval date of the drugs and their first use. To further explore the rise and pattern of each drug’s dissemination, we analyzed the trend of the cumulative number and total of new prescriptions for each prefecture. The results showed that the first month of new cancer drug prescriptions varied across prefectures. On average, they lagged by up to 2 months in the slowest prefectures, whereas the variation was almost nonexistent for diabetes drugs. The patterns of dissemination varied more among cancer drugs across the seven Japanese geographical regions. After the initial prescription, the number of prescriptions showed a steep rise for most cancer drugs, whereas the increase was gradual for diabetes drugs. In conclusion, the dissemination of cancer drugs had a greater lag time than that of diabetes drugs. Further research is needed to explore the causative factors to ensure that all effective drugs are equally accessible for those who need them.
format Online
Article
Text
id pubmed-9128186
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91281862022-05-25 How are new drugs disseminated in Japan? Analysis using the National Database of Health Insurance Claims of Japan Watanabe, Tomone Sugiyama, Takehiro Imai, Kenjiro Higashi, Takahiro Cancer Sci ORIGINAL ARTICLES Drug lag refers to the difference in the time of a new drug's approval in different countries; the dissemination of the new drug after approval within the countries is another problem. We examined the nationwide dissemination of 11 cancer drugs approved in Japan between 2011 and 2015 using the National Database of Health Insurance Claims data. We extracted data on the number of cancer drug prescriptions from 47 prefectures and associated demographic information, such as age and sex. Eight diabetes drugs were also examined for comparison. We observed a lag between the marketing approval date of the drugs and their first use. To further explore the rise and pattern of each drug’s dissemination, we analyzed the trend of the cumulative number and total of new prescriptions for each prefecture. The results showed that the first month of new cancer drug prescriptions varied across prefectures. On average, they lagged by up to 2 months in the slowest prefectures, whereas the variation was almost nonexistent for diabetes drugs. The patterns of dissemination varied more among cancer drugs across the seven Japanese geographical regions. After the initial prescription, the number of prescriptions showed a steep rise for most cancer drugs, whereas the increase was gradual for diabetes drugs. In conclusion, the dissemination of cancer drugs had a greater lag time than that of diabetes drugs. Further research is needed to explore the causative factors to ensure that all effective drugs are equally accessible for those who need them. John Wiley and Sons Inc. 2022-03-28 2022-05 /pmc/articles/PMC9128186/ /pubmed/35266252 http://dx.doi.org/10.1111/cas.15322 Text en © 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle ORIGINAL ARTICLES
Watanabe, Tomone
Sugiyama, Takehiro
Imai, Kenjiro
Higashi, Takahiro
How are new drugs disseminated in Japan? Analysis using the National Database of Health Insurance Claims of Japan
title How are new drugs disseminated in Japan? Analysis using the National Database of Health Insurance Claims of Japan
title_full How are new drugs disseminated in Japan? Analysis using the National Database of Health Insurance Claims of Japan
title_fullStr How are new drugs disseminated in Japan? Analysis using the National Database of Health Insurance Claims of Japan
title_full_unstemmed How are new drugs disseminated in Japan? Analysis using the National Database of Health Insurance Claims of Japan
title_short How are new drugs disseminated in Japan? Analysis using the National Database of Health Insurance Claims of Japan
title_sort how are new drugs disseminated in japan? analysis using the national database of health insurance claims of japan
topic ORIGINAL ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128186/
https://www.ncbi.nlm.nih.gov/pubmed/35266252
http://dx.doi.org/10.1111/cas.15322
work_keys_str_mv AT watanabetomone howarenewdrugsdisseminatedinjapananalysisusingthenationaldatabaseofhealthinsuranceclaimsofjapan
AT sugiyamatakehiro howarenewdrugsdisseminatedinjapananalysisusingthenationaldatabaseofhealthinsuranceclaimsofjapan
AT imaikenjiro howarenewdrugsdisseminatedinjapananalysisusingthenationaldatabaseofhealthinsuranceclaimsofjapan
AT higashitakahiro howarenewdrugsdisseminatedinjapananalysisusingthenationaldatabaseofhealthinsuranceclaimsofjapan